Fig. 2From: Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter studySurvival of patients with advanced NSCLC. a Overall survival of all cohorts. b Overall survival by fusion partner. c Overall survival by TP53 mutation status. Tick marks indicate censoring of the data at the last time the patient was known to be alive. d Overall survival of TP53 loss-of-function and TP53 wildtype patients. Abbreviations: mOS - median overall survivalBack to article page